-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the AACR meeting on April 10, 2021, Immunesensor made its debut.
The pipeline of Immunesensor is based on the research of academician Chen Zhijian.
Chen Zhijian discovered that the DNA receptor is cGAS and has systematically studied in the field of cGAS-STING for many years.
Immunesensor's ADC technology is to couple STING agonists to antibodies.
At this AACR meeting, another biotechnology company Tallac also introduced its new ADC technology TRAAC.
TRAAC technology is the site-specific coupling of antibodies to TLR9 agonists (oligonucleotides containing CpG).
TLR9 agonists also have the effect of activating natural immunity and promoting anti-tumor immune response.
The picture below shows Tallac's R&D pipeline, with the fastest progress being the CD22 ADC.
Mersana also reported on the progress of the STING agonist conjugated antibody XMT-2056 at the AACR meeting.
Its design idea is similar to that of Immunesensor.
The activity of XMT-2056 is more than 100 times higher than that of free toxin.
Based on the ADC technology, Mersana has verified the anti-tumor activity of multiple targets in in vivo experiments.
Previously, we have introduced Silverback’s ImmunoTAC technology to couple TLR8 agonists to antibodies.
Bolt's IASC technology is antibody-conjugated TLR7/8 agonist.
Sutro's iADC technology simultaneously couples toxins and TLR agonists to antibodies.
The editor concludes that innate immunity and ADC technology have opened up a new perspective.
In just a few years, a large number of TLR agonists, STING agonists, etc.
have emerged, and they have been well proven before clinical.
Some drugs under development have entered the clinic.
During the research phase, we look forward to its follow-up progress.
The copyright statement welcomes personal forwarding and sharing.
Any other media or website that needs to reprint or quote the copyrighted content of this website must be authorized and marked "Reprinted from: Biopharmaceutical Editor" in a prominent position.
The pipeline of Immunesensor is based on the research of academician Chen Zhijian.
Chen Zhijian discovered that the DNA receptor is cGAS and has systematically studied in the field of cGAS-STING for many years.
Immunesensor's ADC technology is to couple STING agonists to antibodies.
At this AACR meeting, another biotechnology company Tallac also introduced its new ADC technology TRAAC.
TRAAC technology is the site-specific coupling of antibodies to TLR9 agonists (oligonucleotides containing CpG).
TLR9 agonists also have the effect of activating natural immunity and promoting anti-tumor immune response.
The picture below shows Tallac's R&D pipeline, with the fastest progress being the CD22 ADC.
Mersana also reported on the progress of the STING agonist conjugated antibody XMT-2056 at the AACR meeting.
Its design idea is similar to that of Immunesensor.
The activity of XMT-2056 is more than 100 times higher than that of free toxin.
Based on the ADC technology, Mersana has verified the anti-tumor activity of multiple targets in in vivo experiments.
Previously, we have introduced Silverback’s ImmunoTAC technology to couple TLR8 agonists to antibodies.
Bolt's IASC technology is antibody-conjugated TLR7/8 agonist.
Sutro's iADC technology simultaneously couples toxins and TLR agonists to antibodies.
The editor concludes that innate immunity and ADC technology have opened up a new perspective.
In just a few years, a large number of TLR agonists, STING agonists, etc.
have emerged, and they have been well proven before clinical.
Some drugs under development have entered the clinic.
During the research phase, we look forward to its follow-up progress.
The copyright statement welcomes personal forwarding and sharing.
Any other media or website that needs to reprint or quote the copyrighted content of this website must be authorized and marked "Reprinted from: Biopharmaceutical Editor" in a prominent position.
